Download Case Reports Cancer

Case Reports
Cancer
Bladder Cancer
NAME/Y.I.
AGE/39
SEX/Female
AREA/unknown
History of Past Diseases and Treatments
The patient developed rheumatoid arthritis while she was studying to be a dentist at a dental school. She opened her
own dental clinic at the age of 29 and had a busy practice. She had severe hematuria in February 1999 and was
admitted to the urology department at a nearby hospital for examination. Histopathological tests revealed bladder
cancer. She was recommended to have an operation, but she refused due to QOL issues. She chose to undergo
treatment mainly consisting of alternative medicine, trying various options. On June 5, she visited this hospital for
treatment. She was immediately put on a restricted diet based on semi-fasting. She was also recommended to take a
daily dose of 4-5 g of Rice Bran Arabinoxylan Compound (RBAC) to enhance immunity and plant enzymatic foods to
improve her blood profile. Pain upon urination began to subside two weeks after the start of treatment. In early July,
one month after initiating treatment, hematuria was lighter, suggesting a rapid reduction in the size of the tumor. The
value of the tumor marker NMP-22 (normally 12 or less) decreased from 58 on May 25, to 10 on July 28.
Evaluation
The bladder cancer decreased in size over a short period due to treatment with a restricted diet and
immunopotentiation. It ultimately disappeared, as determined by tumor marker test results. The patient’s young age
and great self-healing ability may have contributed to this improvement. However, since adherence to a conventional
lifestyle is likely to cause a recurrence and new tumor growth, the patient needs careful follow-up, including health
guidance.
Breast Cancer
NAME/K.T.
AGE/39
SEX/Female
AREA/Japan
NAME/M.D.
AGE/74
SEX/Female
AREA/Japan
Clinical Record and Treatment
Two patients with breast cancer took 3g of Rice Bran Arabinoxylan Compound (RBAC) per day continuously in order
to confirm the effectiveness of RBAC.
Patient K.T. age 39, had surgery on her right breast due to cancer. One and a half years after the operation, she had
a combined treatment of chemotherapy and RBAC at a hospital in Kochi prefecture, Japan. Tumor marker CA15-3
was 268 at the beginning. The rise in the marker has been inhibited by the combined therapy and she has since
maintained her health and enjoys a normal life, although she continues to visit the hospital on a regular basis. She
took RBAC from February 24, 1997 to December 3, 1998.
Patient M.D., 74 years old, arrived at the hospital with a tumor protruding from her breast like a cauliflower. The tumor
markers were 63.4 for CEA and 14.6 for CA15-3 at that time. She was hospitalized on August 2, 1997 when she
started taking RBAC at a dose of 3 grams a day. On October 2, 1997, the tests showed that the markers stayed at
15-3 65.1 for CEA and 20.1 for CA. Surgery was performed at her request in January 1998. The patient continued to
1
take RBAC and the marker CEA declined to 3.5 as of February 10, 1999. RBAC seemed to help prevent cancer
recurrence and she has maintained good health since. The period that she took RBAC was from August 2, 1997 to
February 10, 1999.
Patient: M.D., 74 years old
70
63
ＣＡ１５－３
65
64
60
Tumor markers
ＣＥＡ
50
40
30
14
20
20
21
10
3.5
0
8/2/1997
10/2/1997
1/5/1998 surgery
2/10/1999
Evaluation
This small-scale clinical study involving two female patients seems to confirm the effect of RBAC for breast cancer.
Either case, tumor markers did not increase during the period of RBAC administration. RBAC did inhibit the growth of
tumors. It has prolonged the life of each patient since all the patients have continued to maintain a healthy and stable
condition.
NAME/C.E.
AGE/51
SEX/Female
AREA/U.S.A.
Clinical Record and Treatment
A 51 year old patient in California found a tumor in her left breast, as confirmed by biopsy at a hospital on December
19, 1994. She first took hormone therapy and radiotherapy, which were unsuccessful. On March 7, 1995, she began
taking 3 grams of Rice Bran Arabinoxylan Compound (RBAC). Her NK cell activity nearly doubled as compared to
baseline, and a mammogram taken on July 31, 1995, revealed the absence of tumors, not even a benign one.
100
90
NK-cell Activity (%)
80
70
66.8
66
11/1/1995
5/1/1996
1/1/1997
55
60
40.8
50
40
65
36
30
20
10
0
03/1995 baseline
4/1/1995
5/1/1995
2
Another test done in January 1997 did not detect a tumor, and she has continued to take RBAC to prevent relapses.
Evaluation
After receiving hormone therapy and irradiation therapy, the patient took RBAC as a measure to prevent cancer
recurrence. While taking RBAC, the patient's NK cell activity increased gradually and now the patient maintains twice
the level of NK cell activity as compared to the initial levels. This improvement is thought to have helped prevent a
recurrence.
NAME/M.L.
AGE/50
SEX/Female
AREA/U.S.A.
Clinical Record and Treatment
On August 3, 1991, a tumor was discovered in the patient's left breast during a breast examination. The patient
started taking 3 g of Rice Bran Arabinoxylan Compound (RBAC) per day for immunotherapy on September 3, 1992.
Subsequently, a CAT scan performed on March 13, 1993 found no tumor. The patient's right breast was also normal
and healthy, as indicated by a mammogram conducted on January 26, 1995.
100
90
NK-cell Activity (%)
80
72.6
70
59.6
58.9
58.7
6/1/1993
9/1/1993
12/1/1993
58
60
63
50
40
30
20
10
5
0
01/1992
baseline
1/1/1993
3/1/1993
2/1/1994
Evaluation
The administration of RBAC would have helped to heal the patient's breast cancer within two years. Her NK cell
activity increased rapidly and remained at a high level during RBAC administration.
NAME/M.M.
AGE/48
SEX/Female
AREA/Japan
Medical History
The patient noticed a swollen lymph node on the left side of her neck. She visited a nearby hospital for a complete
medical checkup, which revealed a tumor in her left breast and the swelling in her neck was diagnosed as a
metastatic lesion. It was determined to be inoperable and she was put on chemotherapy with three anticancer drugs
(Adriamycin, 5FU and cyclophosphamide). The tumor in her left breast was involute and the lymphatic metastasis
shrank temporarily. Later, the metastasis resumed and the tumor marker did not decrease, so the patient received
four more sessions of chemotherapy. In January 2000, a weekly infusion with docetaxel wettable powder (Taxotere)
was initiated and maintained until July of that year because there was an increase in lymphatic metastasis and tumor
3
maker values. On January 18, the patient visited our clinic seeking immunopotentiation therapy. On January 28, she
began to receive massive weekly infusions of vitamin C and Chinese medicine (Hochuekkito 7.5 g/day), as well as
Rice Bran Arabinoxylan Compound (RBAC) at a dosage of 3 g per day (1 g three times daily) as immunopotentiation
therapy. In June of the same year, shrinking of the lymph swelling was confirmed. Hormone therapy (Hysron
progesterone preparation) replaced Taxotere in August. Since then, there has been no recurrence or metastasis as
confirmed by radiography, CT and ultrasonography, although tumor markers have been fluctuating.
Evaluation
After the patient began taking RBAC as part of her immunopotentiation therapy, in addition to chemotherapy, NK cell
activity increased and tumor size decreased. Eight months after treatment with RBAC, NK cell activity increased
more than two-fold, which seemed to have contributed in preventing recurrence.
NAME/J.B.
AGE/46
SEX/Female
AREA/Germany
02/1998: Diagnosis: Breast cancer, T3 (tumor >5cm), G2, plum-sized primary tumor; could not be removed
completely from healthy tissue. The patient rejected the removal of lymph nodes as well as chemotherapy and
radiation. Alternative treatment: Mistletoe therapy, Vitamin C infusions, change in diet, orthomolecular nutrients,
detoxification by fasting for 42 days.
10/2000: Removal of a recurrence.
01/2001: Five times whole-body hyperthermia treatment, detection of low Natural Killer Cell activity.
01/2001: Test results after hyperthermia period: (> 25) NK/Ctx (cytotoxicity); basal 5% (> 40) NK/Ctx; IL-2 stim 13%.
Conclusion: Despite high-dose vital nutrient therapy, Vitamin C infusions, mistletoe therapy, change in diet and
whole-body hyperthermia, there was no increase of Natural Killer Cell activity.
06/2001: Initiate treatment of Rice Bran Arabinoxylan Compound (RBAC), 3g/day.
Test results 25.06.01 (>25) NK-CTX (cytotoxicity); basal 28% (>40) NK-CTX; IL-2 stim 31%.
Result 14.07.01 (>25) NK-CTX; basal 36% (>40) NK-CTX; IL-2 stim 38%.
Conclusion: Increase of Natural Killer Cell activity from 5% to 36% within 6 weeks. Since then the patient has been in
good physical and psychological condition. Additionally, according to the latest measurement in November, 2011, her
haemogram (CBC) is optimal. Tumor recurrence hasn’t been detected since October 2004. To support her immune
system the patient occasionally does a round of RBAC treatment consisting of 1-3g RBAC daily for several weeks.
Colon Cancer
NAME/S.B.
AGE/64
SEX/Male
AREA/Japan
History of Past Diseases and Treatments
In December 1998, the patient found large quantities of blood in his stool, so he visited a nearby hospital to undergo
a colonoscopy. As a result, he was diagnosed with colon cancer. He was recommended, but refused, a surgical
4
operation and he then visited this hospital in January 1999. Although he was also recommended to have surgery at
this hospital, he instead strongly requested a conservative treatment consisting mainly of immunotherapy to prevent
further cancer growth. He was treated with a restricted diet and a combination of the immunopotentiator Rice Bran
Arabinoxylan Compound (RBAC), additional health foods, growth hormone and thymus hormone. RBAC was given
in a six-day cycle, with four successive days of dosing at 5 g daily and then two days off. After one year of treatment,
he noticed his stool was thinning and thought the cancer was growing. After a complete medical checkup, it was
found that the cancer was not growing but had necrotized completely. The stool was thinner because the mass of the
necrotized cancer lesion was occluding the colon.
Evaluation
The colon cancer was progressive and required surgery. Considering QOL, the patient chose to undergo a treatment
that would enhance his self-healing potential. RBAC was used to play a leading role in enhancing immunopotency.
Lung Cancer
NAME/S.K.
AGE/67
SEX/Male
AREA/Japan
Clinical Record and Treatment
A male Japanese patient, aged 67, lost substantial weight and suffered from a hacking cough with sputum, which
brought him to the department of Respiratory Medicine and Surgery at a hospital in Osaka, Japan in August 1996. At
the examination he was diagnosed with lung cancer complications and pulmonary tuberculosis. In October 1996, he
was first treated with antibiotics for pulmonary tuberculosis, and then with irradiation therapy for lung cancer. In
December of that year, a tumor was removed by resection of the lower half of his right lung. In January 1997 the
patient left the hospital. Five months later, he felt pain in his right thoracic region and upon examination, multiple bone
metastases were found. Tumors then spread all over the patient’s body, with the primary site in the ribs of his right
thoracic region. Three grams a day of Rice Bran Arabinoxylan Compound (RBAC) were administered with an
analgesic morphine. Six months after taking RBAC, the dosage of morphine was gradually reduced as his pain
subsided. In June 1998, his pain ceased and he was able to discontinue morphine. The tumor marker was 16.8 in
June 1997 at the start of RBAC administration, which declined to 7.6 in December 1997 and 6.7 in June 1998.
Significant improvement was observed with a bone scintigram. Metastasis to bone had clearly lessened.
20
CEA
16.8
10
7.6
6.7
0
6/1/1997
12/1/1997
5
6/1/1998
Changes caused by RBAC Treatment
The patient felt the type of pain in his right thoracic region change 1 month later after taking RBAC, and the pain had
obviously lessened 6 months later.
Evaluation
In this case, metastasis had developed very rapidly and was gradually slowed and shrunk after RBAC was
administered. As of June 1998, the tumor marker was still higher than the normal level, but a continuous intake of
RBAC would lead to further improvement and eventual remission. RBAC treatment was used in a very similar case of
lung cancer involving a 77 year old female patient with a very similar treatment, leading to an improvement in bone
metastasis and a reduction in pain.
NAME/A.G.
AGE/unknown
SEX/Male
AREA/Germany
28/07/2005: Medical evaluation: strong suspicion of a bronchial carcinoma located centrally in the left main bronchus,
space occupying size of 3.5 x 3 cm.
08/09/2005: Start RBAC (Rice Bran Arabinoxylan Compound) treatment: 3g daily for one month, continue with
1g daily thereafter.
08/09/2006: First cycle of chemotherapy with Taxol and Cisplatin.
16/09/2005: Histopathology results: undifferentiated non-small cell carcinoma, G3 (high
grade), suspicion of a
bronchial carcinoma located centrally on the left main bronchus.
16/09/2006: Initiate thirteen cycles of induction chemotherapy with Paclitaxeland Cisplatin II radiochemotherapy.
28/09/2005: Diagnosis: Bronchial carcinoma left side (NSCLC), T4 (invasive), NO (no lymph nodes), MO (no distant
metastasis).
29/11/2005: ESPATÜ-study: neoadjuvant induction chemotherapy, radiochemotherapy with Paclitaxel and Cisplatin
II.
21/12/2005: Initial neoadjuvant radiochemotherapy proceeded without complications. Later will require definitive
radiochemotherapy up to 71Gy (ESPATÜ study with 88 participants).
Rehabilitation therapy to start in February, 2006 (previous skull-MRI). Prophylactic whole-skull radiation.
14/06/2006: Diagnosis: Central infarction (after radiation) in lower lobe, left side. Non-small cell bronchial carcinoma
left lung, ED 08/05 (T4, NO, MO). COPD Therapy: transthoracic swaged left thoracic.
Radiochemotherapy until 02/2006.
19/09/2006: Thoracic CT with contrast agent. Technique of investigation: lateral topogram, spiral CT. Result: still 2 x
1.5 cm sized, smooth, circumscribed liquid mass, left dorsolateral, situated in the apical segment of the lower lobe.
Most likely shrinking scar, necrotic remains of tumor or shrinking abscess cavity.
6
The original large tumor in the left, central lung is almost imperceptible after chemotherapy and radiation.
10/11/2006: Imaging: FDG-PET/CT native and contrast agent from 02.11.06. Question: Recurrence? Evaluation: No
evidence of vital tumor manifestation. The morphologically detectable lung lesions are most likely post-radiogenic or
post-inflammatory induced.
End of 2007 Only 2 out of 88 participants from the ESPATÜ study are still alive.
02/2008: Patient is free of pain and continues with 250mg RBAC daily.
01/2012: The patient is still well and the sole survivor of the study.
Nephroblastoma
NAME/T.J.
AGE/unknown
SEX/unknown
AREA/Slovakia
Medical History:
History: Grandfather had operation for Grawitz renal tumor, rectosigmoid cancer, and is presently in remission.
Personal History: Child from first pregnancy, p.h. 3170g, length 51cm, Abgar score 10.
Social History: Good
Nutrition and Elimination: Good appetite, urination without difficulty, haematuria, regular bowel movement
Evidence of Abuse: Negative
History of Allergies: Negative
CHS: A 4 ½ year old patient was admitted to the oncology clinic with diagnosis of suspicious Morbus Wilms
syndrome. 48 hours ago the kindergarten teacher noticed
macroscopic haematuria (blood in urine) and on the
following day the mother also observed the presence of haematuria in the boy, without dysuria (painful urination). The
patient was then examined by the urologist when ultrasound screening indicated a suspicious left kidney tumor.
Additional CT examination was carried out with contrast medium administration, confirming a left kidney tumor of
possible malignant etiology. The size of the kidneys were 4.5 cm and tumor 7.5 cm. Because the tumor originated on
the upper region of the kidney, no asymmetry was visible (i.e. bulging of the abdominal cavity), which is one of the
most common initial symptoms of this type of cancer in young children.
Preoperative period
The patient was admitted to the Oncology Clinic DfN the following day where preoperative chemotherapy was
administered to localize the nephroblastoma (kidney tumor) according to the protocol from the SIOP 2001
nephroblastoma trial with the drugs 4x Vinkristin, 2x Cosmogen and 3x Aktinomycin. Preoperative chemotherapy
was administered to reduce and limit the growth of the tumor because of surrounding critical organ and tissue
structures. The administration of chemotherapy for a 6 week period did not reduce the tumor size, but the effect was
sufficient considering the surrounding area, allowing for preoperative preparation. During the administration of
preoperative chemotherapy there was an unexpected rapid decrease in leukocytes from the original 8.9 to 1.5 g/L.
Because of this low leukocyte level the operation was not possible. Transfer factor, an immunostimulant, was given to
the patient and after consulting with the doctor, the mother started giving him Rice Bran Arabinoxylan Compound
7
(RBAC). There was a significant rise in leukocytes within a few days, from the original 1.5 to 4.0 g/L. Because of the
success of the treatment, the operation for nephrectomy (kidney removal) and epinephrectomy (adrenal removal)
th
was performed on the 7 day of RBAC administration. The transfer factor was administered only once.
Operation
Patient was given general anesthesia. Laparotomy procedure to remove his left kidney and left adrenal.
Postoperative period - chemotherapy
The operation was performed on 21.6.2005 and 21 days later, after review of histology results, postoperative
chemotherapy was started. Considering the fact that histology results indicated intermediate risk, stage II, the patient
qualified to be included in an internationally coordinated study whose center is located in Amsterdam. By means
of random selection, he was placed in the group that received chemotherapy with the lowest dosage of cytostatics (to
prevent multiplication of tumor cells) in combination with two drugs, Vinkristin and Cosmogen, instead of
the
standard combination of 3 drugs. After 6 weeks of chemotherapy the patient felt sick. According to the child´s own
words it was as if the disease had not subsided. Leukocyte values during this period were between 6- 9 g/L. After
evaluating the clinical condition of the patient, chemotherapy was modified to the standard combination of Vinkristin,
Cosmogen and Doxorubicin, administered once per week, followed by an additional Doxorubicin injection over the
next 6 weeks. The result of the strong immunosuppression was a decrease in leukocytes from 6 to 0.8 g/L over the
course of less than two weeks. Chemotherapy was subsequently suspended due to leukopenia (significantly low
white blood cell count). Starting from this point, RBAC was added to the treatment in dosages of 1000 mg /day, which
was calculated based on a weight of 15 kg. During the course of the week, the CBC (complete blood count) improved
as a result of the rise in leukocytes, enabling chemotherapy to proceed according to schedule. RBAC was not
reduced during chemotherapy and thanks to the immunostimulatory effect of the of the nutritional supplement, the
child was able to undergo chemotherapy without interruption or delay due to leukopenia. Despite significant
immunosuppression during the administration of chemotherapy and RBAC, the child was not overcome by any
serious bacterial or viral infection.
RBAC was given to the patient at the stated dosage for a total of 9 months, with an obvious positive clinical effect
documented by consistent laboratory results.
Reconvalescence period
After the completion of chemotherapy in February 2006, the patient was given RBAC for an additional 18 months in
reduced dosages of 500 mg/day. During this period the patient was healthy and attended compulsory preschool
without acquiring any bacterial or viral infections.
Final summary
The present case study of an oncology patient whom was administered the nutritional supplement RBAC during and
after chemotherapy provides sufficient clinical evidence to support the efficacy of the preparation. The immune
enhancing effect of the dietary supplement RBAC, specifically on NK (natual killer) cells and TNF (tumor necrosis
factor), enabled the patient to continue with chemotherapy without any delay caused by accompanying leukopenia.
The more than 100,000 times increase in the number of NK cells lead the charge against the surviving tumor cells in
the patients blood. It can be concluded, based on wide clinical experience backed by laboratory findings, that the
8
combination of RBAC with targeted chemotherapy is a treatment that can be used therapeutically for solid tumors.
Ovarian Cancer
NAME/unknown
AGE/53
SEX/Female
AREA/unknown
There is an interesting case of combination therapy using chemotherapy and Rice Bran Arabinoxylan Compound
(RBAC) together which resulted in shortening the period of achieving a complete clinical remission to just two
months. It would normally take 3 to 4 months on average to heal a patient of cystadenoma with only chemotherapy.
A female patient was 53 years old, when on February 11, 1993 she was diagnosed with ovarian cancer. Her clinical
symptoms included swelling of the breasts and abdominal distention. Pathological findings were high grade serous
papillary cyst adenocarcinoma with areas of undifferentiation and frequent mitosis. The tumor involved both ovaries,
with multiple peritoneal implants. The lymph nodes were tumor free. Cytospin and button section peritoneal fluid
showed malignant cells.
The patient underwent surgery, followed by a course of chemotherapy consisting of cysplatin and 5FU. Concurrently,
RBAC was administered orally in a dose of 3 grams a day. The progress of her condition was monitored by
sequential determinations of CA-125 (tumor marker). The baseline CA-125 after surgery was 327 U/ml. A significant
reduction in the level of CA-125 was found 3 weeks after the combination therapy and a further reduction in CA-125
occurred 6 weeks after the treatment. The antigen level reached that of controls (0-35 U/ml). CA-125 maintained at
low levels in subsequent examinations; 23 and 18 U/ml at 9 and 12 weeks respectively, after the treatment.
Baselines of NK cell activity for the patient were 2.9, 7.4 and 15.2% at E:T ratios 12:1, 25:1 and 50:1 respectively. NK
cell activity was further monitored at different intervals after the combination therapy using chemotherapy and RBAC.
The results showed a significant enhancement in NK cell activity as early as 3 weeks after the treatment. An increase
in NK cell activity was observed at all E:T ratios as follows; 6.6% at 12:1, 20.2% at 25:1 and 37.4% at 50:1. NK cell
activity maintained a high level at one month after the treatment and an additional increase was achieved at 4.5
months, namely, 11.7, 41.1 and 72.6% at 12:1, 25:1 and 50:1 respectively.
Also, a flow cytometry study was conducted to evaluate the percentage of CD56 cells. Results showed no significant
change in NK cells after the treatment as compared to NK cells before the treatment.
Prostate Cancer
NAME/C.J.
AGE/68
SEX/Male
AREA/U.S.A.
Clinical Record and Treatment
An American patient aged 68 was diagnosed in July, 1995 at a hospital in California. Two types of chemotherapy
treatments were initiated immediately, but were unsuccessful. An examination conducted on August 25, 1995,
revealed a Gleason score of 9. There was no significant improvement despite the chemotherapy. In January, 1996 he
started taking 3 grams of Rice Bran Arabinoxylan Compound (RBAC) per day. In April, 1996 the patient had a
cryoprostatectomy without hormone therapy. He recovered his ability to ejaculate on November 10, 1996. His NK cell
9
activity increased one year after the RBAC treatment had started. His tumor marker PSA level shows that he is in full
remission now.
90
80.3
NK-cell Activity (%)
80
70
60
44.5
50
40
33.7
35.5
01/1996
baseline
4/1/1996
30
20
10
0
5/1/1996
12/1/1996
Evaluation
This patient took RBAC only after he discovered that the chemotherapy was unsuccessful. Three months later, the
tumor had involuted, making it possible to remove by means of cryoprostatectomy. It seemed that RBAC helped the
patient to restore his ability to ejaculate. His NK cell activity has since been maintained at a high level by the
administration of RBAC. The results suggest that in this case, RBAC had positive effects in inducing involution of the
tumor and in preventing tumor recurrence.
Case Reports
NAME/T.H.
Leukemia
AGE/26
SEX/Female
AREA/Germany
17/11/2004: Referral to hospital with a haemoglobin (Hb) value of 5.5. Bone marrow puncture resulting in diagnosis
of ALL (Pro-B-ALL) with 97% B-cells.
18/11/2004: Transfer to the intensive oncological care unit. Hemoglobin value of 4.6.
19/11/2004: Start cortisone treatment, daily EPO injections.
20/11/2004: Further deterioration of the patient’s general condition, Hb-value declines to 3.7. Initiate chemotherapy
(Vincristin).
21/11/2004 Second round of chemotherapy (VCR, dexamethasone, 50mg Daunoblastina).
22/11/2004: Hb-value 3.5; leukocytes 1.3; thrombocytes 4. Administration of G-CSF (granulocyte-colony stimulating
factor).
24/11/2004: Absolute bed rest prescribed until 25.11.2004. Increasing signs of fatigue and exhaustion. Administer
10
oxygen.
26/11/2004: Hb-value declines to 2.1. Conversation with medical staff because of acute life-threatening danger. Third
round of chemotherapy.
27/11/2004: Deterioration of general condition.
28/11/2004: Transfer to single bedroom (isolation), Hb-value declines to 1.4. Initiate intake of RBAC (Rice Bran
Arabinoxylan Compound) (nutritional supplement) 3g per day (at patient’s own risk).
29/11/2004: EPO-injection advanced for one day.
01/12/2004: Hb-value remained stable at 1.4.
03/12/2004: Fourth round of chemotherapy.
05/12/2004: Hb-value increases to 1.9. Thrombocytes octuplicate (increase eightfold) to 32.0. Discontinue cortisone
treatment.
06/12/2004: End of isolation. EPO-injection (Aranesp).
07/12/2004: Removal of IV tubes, as sufficient fluids can be taken orally.
09/12/2004: Bone marrow puncture; blasts are <5%, extreme bone marrow regeneration and increase of blasts.
10/12/2004: Fifth round of chemotherapy.
13/12/2004: Transfer patient to the regular unit. Hb-value increased to 4.3.
16/12/2004: Hb increased on 5.0, thrombocytes to 180000.
17/12/2004: Sixth round of chemotherapy.
18/12/2004: Hb increased to 5.8; thrombocytes are 225000; leucocytes are 10.9.
20/12/2004: Hb 6.1; thrombocytes are 220000; leukocytes 5.9. Waiting for increase of Hb-value to at least 90g/l,
preferably greater than 100g/l, then continuation of the treatment.
28/12/2004: Continuation of the treatment.
24/01/2005: Hb 12.5; thrombocytes 289000; Leukocytes 4.9.
11
25/01/2005: Initiate ALL induction therapy stage 2 (Endoxan 1670, Alexan 1000, Purinethol 100 mg daily) +
Granozyte + 2x 15mg MTX (into bone marrow) + for the protection of the bladder: Uromitexan 400mg/h 0-4-8.
29/01/2005: Adjourn chemotherapy due to headache and recurrent vomiting (depending on the position).
28/02/2005: Continuation of chemo induction-stage II.
02/03/2005: Hb 8.7; thrombocytes 204000; leukocytes 24.6 (G-CSF).
04/03/2005: End of therapy.
08/03/2005: Start with prophylactic radiation of the skull at 12 Gy (gray unit) 6x, at the radiation clinic in Ludwigsburg.
18/03/2005: Hb 8.6; thrombocytes 70000; leukocytes 2.8.
23/03/2005: Inpatient admission, referral to hospital RBK in Stuttgart.
24/03/2005: Hickman implantation. Laboratory: Hb 6.8; thrombocytes 64000; leukocytes 1.6.
11/04/2005: Whole-body radiation in Heidelberg, TBI 12Gy.
12/04/2005: Laboratory: Hb 12.8; thrombocytes 78000; leukocytes 3.58.
15/04/2005: Laboratory: Hb 11.6; thrombocytes 64000; leukocytes 3.3.
15/04/2005: Admitted to the RBK in Stuttgart.
16/04/2005: Myeloablative therapy with cyclophosphamide (120mg/kg body weight). Start with high-dosed chemo
Endoxan.
18/04/2005: Discontinue RBAC intake.
6
19/04/2005: Stem cell transplantation (transplanted number of cells: 5.04 x 10 /kg body weight). CD34 pos. cells,
GvHD. Prophylaxis: CSA mirror adapted, MMF transplant complications: grade IV neutropenia, grade IV
thrombocytopenia, grade III anemia, "minor bleeding", gross hematuria, multiple petechia, subarachnoidal
hemorrhage (mouth).
09/05/2005: Hb 11.1; thrombocytes 151000; leukocytes 4.0. Medications: folic acid, Multibionta, Aranesp,
Pantoprazole, magnesium preparation, Levofloxacin, Metronidazole, Fluconazol, Cyclosporin (Sandimmun),
Mycophenolate Mofetil (Cellsept).
09/01/2006: End of immunosuppression, discontinuation of Sandimmun.
12
13/02/2006: Hb 10.7; thrombocytes 131000; leukocytes 4.0. Start with RBAC 1g daily (for about 3 months).
09/03/2006: Hb 11.2; thrombocytes 143000; leukocytes 4.8.
20/04/2006: Hb 11.7; thrombocytes 178000; leukocytes 4.7.
09/05/2006: Discontinue RBAC intake.
31/05/2006: Hb 11.3; thrombocytes 144000; leucocytes 4.1.
01/06/2006: Return to work for 15 h / week.
05/10/2006: Hb 12.4; thrombocytes 225000; leukocytes 4.4; ESR 40/80.
07/10/2006: Fever up to 39.5°C.
20/10/2006: RBAC- 4 tablets of RBAC (=2g) twice daily. After 3 days, 1 x daily (=1g) (in total 50 tablets).
13/11/2006: Hb 11.8; thrombocytes 131000; leukocytes 4.3. Liver enzyme parameters continue to decline.
20/02/2008: Patient feels very well and healthy, blood values are optimal.
Case Reports
NAME/O.T.
Lymphoma
AGE/75
SEX/Female
AREA/Japan
Clinical Record and Treatment
In November 1998, a 75 year old Japanese patient had surgery to remove her left breast due to primary malignant
lymphoma. She then received hormone therapy in six cycles and completed it at the end of April 1999. The patient
had a local recurrence, which was found by an ambulatory medical examination in June 1999. Tumor marker CA
15-3 was 85U at that time. She received chemotherapy consisting of Melphalan (4mg for 4 days) for the first week,
Methotrexate (2.5 mg for 3 days) for the second week, Procailazine (100 mg for 3 days) for the third week and
Cyclophophamide (50 mg every day) for the fourth week. In addition, she took 3 grams of Rice Bran Arabinoxylan
Compound (RBAC) per day. Significant results had been obtained in the first cycle in that the tumor shrunk and the
level of CA 15-3 declined to 45. After the second cycle, ambulatory treatment appeared possible, and the patient was
able to leave the hospital on July 20, 1999. The patient had 4 cycles of chemotherapy in total. The tumor marker CA
15-3 consistently decreased and then stayed in normal range. A point deserving a special attention is the fact that the
patient could continue ambulatory treatment with only minor adverse effects, despite her age (75). This is considered
to be one of the benefits of RBAC. This may also indicate that RBAC had an effective and synergistic effect with the
chemotherapy. Another interesting aspect in this case is that the patient did not lose her appetite and was able to
maintain her energy during the course of chemotherapy.
13
Changes caused by RBAC Treatment
It is worth noting that the patient did not have a loss of appetite and experienced little loss of energy during the
administration of chemotherapeutics.
Evaluation
In this case, chemotherapy was used to prevent the recurrence of breast cancer. RBAC was added to avoid harming
her immune system, which would also help enhance the effectiveness of chemotherapy. The result was totally
satisfactory. In a RBAC study, it was found it can prevent NK cell activity decline caused by 5FU administration. In
this case, it seems that the adverse effects of chemotherapy were mitigated by RBAC and the patient was able to
maintain physical strength throughout the course of her treatments.
Case Reports
NAME/N.M.
Hepatitis
AGE/48
SEX/Male
AREA/Japan
Clinical Record and Treatment
In early March 1996, the patient felt unusually lethargic and was ultimately diagnosed with chronic hepatitis
(non-viral) and early diabetes at the H polyclinic.
The patient checked in to the clinic on May 30, 1996. After rest and an intravenous injection for Major Minofargen C,
his liver function temporarily stabilized and he was able to leave the clinic after a month. Thereafter, the patient
experienced periodic deterioration in liver function despite continuing IV administration of Major Minofargen C, and
he suffered from chronic hepatitis until the beginning of March 1997. The patient then started taking 3g of Rice Bran
Arabinoxylan Compound (RBAC) per day (1g/dose) and his level of liver function increased to nearly the same level
as they were at the beginning of therapy 12 days earlier. The enzyme levels gradually decreased, reaching the
lowest value one month later. The patient's AST and ALT levels returned to normal one month afterwards. Presently,
the patient's liver function has returned to normal and he is experiencing no other health-related problems.
Changes caused by RBAC Treatment
The patient's energy level increased after RBAC administration, and his unusual fatigue (especially in the afternoon)
gradually abated. The patient was able to sleep and wake normally, had a good appetite, and appeared very healthy.
Evaluation
As indicated by the graph below, the AST and ALT levels temporarily increased after the administration of RBAC,
before steadily decreasing and returning to normal. During RBAC administration, no special treatments were
performed. These results suggest that RBAC protected the patient's liver and its immunopotentiation activity was
effective.
14
Hepatitis B
The clinical effectiveness of Rice Bran Arabinoxylan Compound (RBAC)
in immunotherapy for patients with hepatitis B
Dr. Tran Thi Minh Phuong (Former Vice Dean of Gastroenterology Department)
Abstract:
Hepatitis B virus (HBV) infection is a serious global health problem with devastating consequences of chronic
hepatitis, cirrhosis, and hepatocellular carcinoma.
More efficacious treatments such as mass immunization
programs and safe injection techniques are essential for eliminating HBV infection and reducing global HBV-related
morbidity and mortality. Antiviral therapy has been the primary treatment to date, however conventional treatment
has undesirable side effects and continuous treatment can lead to the development of resistance. Additionally,
antiviral medicines are costly, up to thousands of dollars per year, and are not widely available in many countries
especially in the developing world.
Rice Bran Arabinoxylan Compound (RBAC) is a food supplement that can be combined with conventional treatment
to improve disease outcome. The following three cases describe patients with hepatitis B who were treated with the
combination of conventional antiviral therapy and RBAC. In these cases, blood samples were taken to measure liver
function and immunopotency, and the results were compared with clinical changes and imaging . Improvements were
noted in most of the cases. Finally, some recommendations were provided to enhance the effectiveness of treatment
progress.
Key words: Hepatitis B virus infection, antiviral therapy, RBAC
Methods
The food supplement RBAC was ingested orally at dose of 1 pack/24h and combined with antiviral medicines and
liver support supplements. The therapeutic effectiveness was assessed by measuring liver enzyme levels, immune
parameters and ultrasound images.
Results
1. Case 1 (male, 43 years, hepatitis B virus)
The patient had been diagnosed with hepatitis B in 2000, presenting with symptoms of fatigue, slight fever, and dark
urine. He underwent treatment with liver support supplements, antiviral therapy (Nucleozid) and RBAC (1 pack/24h).
After 18 months of treatment, his biochemical test results improved. The test results and treatment progress are
shown in table 1.
Family history: this patient has a younger brother who also has HBeAg (+), and had been treated with antiviral
medicine (Tenofovir) and RBAC 1 pack/24h.
Table 1: Case 1 (male, 43 years, viral B hepatitis)
Time of
Clinical
treatment
symptom
Biochemical tests
AST
ALT
FP
(U/l)
(U/l)
(ng/ml)
Ultrasound
test
Viral detection tests
HBsAg
HBeAg
Anti
HBV DNA
Hbc
quantity
(copies/ml)
11/2007
Fatigue,
78
84
(-)
Gallbladder
15
(+)
(-)
(+)
6.91x106
Medicines
(before
yellow
polyps;
treatment)
urine,
gallbladder
digestion
duct:
disorder
hyper-echoic
1.1mm;
texture
1 month of
42
60
-
treatment
Reducing
liver
enzyme medicine,
-
Antiviral
medicine
(Entecavir 0,5mg/24h),
- RBAC 1 pack/24h
2 months
30
36
-
of
- RBAC 1 pack/24h
30
2.8x104
28
-
of
Antiviral
- RBAC 1 pack/24h
32
30
1.84x10
2
Continuously used 2
of
medications
treatment
months
15 months
medicine
(Entecavir 0,5mg/24h),
treatment
12 months
medicine
(Entecavir 0,5mg/24h),
treatment
6 months
Antiviral
Normal
Normal
26.7
24.3
in
3
of
treatment
3/4/2010
(-)
Small
(-)
Unfound
- Stop using antiviral
gallbladder
medicine
polyps
-
RBAC
plus
1
pack/24h
5/7/2010
26
18
(-)
Indication
for
HBV
immunization
2. Case 2 (male, 17 years old and younger brother, 15 years old)
In February 2004, these patients presented with symptoms of fatigue, weight loss, and loss of appetite and were
diagnosed with hepatitis B virus.
Family history: their mother also has HBsAg (+)
- Laboratory tests before treatment:
17 year old male
15 year old male
- Biochemical tests: AST: 210 (UI/l); ALT: 180 (UI/l), FP
- Biochemical tests: AST: 230 (UI/l); ALT: 210 (UI/l),
(-)
FP (-)
- HBeAg (+), HBeAg (+), Anti Hbe (-)
- HBeAg (+), HBeAg (+), Anti Hbe (-)
- HBV DNA qualitative analysis (+++)
- HBV DNA qualitative analysis (+++)
- Ultrasound test: hyperechoic texture, enlarged spleen:
- Ultrasound test: hyperechoic texture, enlarged spleen:
2cm below costal margin
1cm below costal margin
16
+ Treatment: liver support supplement, viral inhibitor (Lamivudine 1 tablet/24h), and RBAC (1 pack/24h).
- Laboratory tests after 6 months of treatment:
17 year old male
15 year old male
- Liver enzymes: AST: 80 (UI/l); ALT: 42 (UI/l)
- Liver enzymes: AST: 78 (UI/l) ; ALT: 46(UI/l)
- HBeAg (+)
- HBeAg (+)
- HBV DNA qualitative analysis: (+)
- HBV DNA qualitative analysis: (+)
- Ultrasound test: hyperechoic texture, splenomegaly
- Ultrasound test: hyperechoic texture, splenomegaly
+ Continuous treatment: liver support supplement, viral inhibitor (Lamivudine 1 tablet/24h), and RBAC (1 pack/24).
- Laboratory tests after 12 months of treatment:
17 year old male
15 year old male
- Liver enzymes: AST: 28 (UI/l); ALT: 40 (UI/l)
- Liver enzymes: AST: 30 (UI/l); ALT: 42 (UI/l)
- HBeAg (+)
- HBeAg (+)
- HBV DNA qualitative analysis: (+)
- HBV DNA qualitative analysis: (+)
- Ultrasound test: hyperechoic texture, splenomegaly
- Ultrasound test: hyperechoic texture, splenomegaly
+ Continuous treatment: liver support supplement, viral inhibitor (Lamivudine 1 tablet/24h), and RBAC (1 pack/24h).
- Laboratory tests after 24 months of treatment:
17 year old male
15 year old male
- Liver enzymes: AST: 30 (UI/l); ALT: 26 (UI/l)
- Liver enzymes: AST: 28 (UI/l); ALT: 24(UI/l)
- HBeAg (+)
- HBeAg (-)
- HBV DNA qualitative analysis
(+)
- HBV DNA qualitative analysis
- Ultrasound test: enlarged spleen, 1cm below costal
()
- Ultrasound test: normal spleen
margin
+ Discontinued drug treatment, continued only with herbal medicine (Chanca Piedra)
- February, 2010:
17 year old male
15 year old male
- Weight loss, loss of appetite
- Liver enzymes: AST: 28 (UI/l); ALT: 20(UI/l)
- Liver enzymes: AST: 40 (UI/l); ALT: 86 (UI/l)
- HBeAg (+), HBeAg quantity: 152.800 UI/l
6
- HBV DNA quantity: 10 copies/ml
- Ultrasound test: hyperechoic texture, enlarged spleen
below costal margin
Treatment: Reduced liver enzyme medicine, viral
Discontinue all medication
inhibitor (Entecavir 0.5g/24h), RBAC (1 pack/24h)
- 8/7/2010:
17 year old male
15 year old male
- Liver enzymes: AST: 32 (UI/l); ALT: 30 (UI/l)
- Liver enzymes: AST: 26 (UI/l); ALT: 18 (UI/l)
- HBeAg (-)
- HBeAg (-)
17
4
- HBV DNA quantity: 10 copies/ml
- HBV DNA quantity: undetected
- Ultrasound test: enlarged spleen below costal margin
- HBeAg qualitative analysis: (-)
- Ultrasound test: normal
- Indication for HBV immunization
- Patients continued herbal medicine (Chanca Piedra) during 6 years of treatment.
3. Case 3 (female, 23 years old, hepatitis B virus)
The patient was diagnosed with hepatitis B virus one month after having a baby, presenting with symptoms of fatigue
and loss of appetite. She also has a brother with HBsAg (+). She underwent treatment with liver support
supplements, RBAC (1000 x 1 pack/24h) and continued breast feeding. The test results and treatment progress are
shown in table 2.
Table 2: Case 3 (female, 23 years, hepatitis B virus)
Time of
Clinical
treatment
symptoms
3/2006
Fatigue,
(Before
loss
treatment)
appetite
Biochemical tests
AST
ALT
FP
(U/l)
(U/l)
(ng/ml)
100
120
of
(-)
Ultrasound
test
Hyper-echoic
Viral detection tests
HBsAg
(+)
HBeAg
(+)
Medicines
Anti
HBV
DNA
Hb
quantity
c
(copies/ml)
(-)
105
texture
-
Reduce
liver
enzyme medicine,
-
RBAC
x
1
pack/24h
-
Keep
breast
feeding
2 months
60
38
-
RBAC
of
pack/24h
treatment
-
Keep
x
1
breast
feeding
-
Appropriate
regime and resting
12/2006
32
28
(-)
(+)
- Antiviral medicine
9 months
(Entecavir
of
0,5mg/24h),
treatment
-
RBAC
x
1
x
1
pack/24h
5/2007
Nor-mal
Nor-mal
103
(-)
14 months
-
RBAC
pack/24h
of
treatment
9/2009
Nor-rmal
Nor-mal
(-)
(+)
Un-detected
- Having 2nd baby
-
RBAC
pack/24h
pregnancy
18
x
1
during
Conclusion and recommendations
The safety of RBAC is easily accepted because it is extracted from rice bran. The current clinical cases further
confirm the safety of RBAC. RBAC is used for immunotherapy to prevent a reduction in physical strength and
appetite. The patients also reported, “When I take it, I feel better”.
The combination of RBAC and antiviral medicines will have the maximum effect on hepatitis B patients who fall into
the following criteria:
+ Patients who have high levels of liver enzymes and HBV DNA quantities.
+ Patients who are compliant with their medication schedule.
The treatment is more effective on HBV patients who are HBeAg (+). Conversely, it is more difficult to treat HBV
patients who are HBeAg (-); therefore taking 2 packs/24h is recommended for these patients.
References:
1. D. Lavanchy (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging
prevention and control measures. Journal of Viral Hepatitis 11(2): 97-10.
2. Lok AS, Hussain M, Cursano C et al (2000). Evolution of hepatitis B virus polymerase gene mutations in
hepatitis B e antigen negative patients receiving lamivudine therapy. Hepatology 32(5): 1145–1153.
3. Lok AS, Zoulim F, Locarmini S et al (2007). Antiviral drug-resistant HBV standardization of nomendature and
assys and recommendations for management. Hepatology 46(1): 254-265.
4. Ghoneum M (1998). Enhancement of Human Natural Killer Cell activitiy by modified Arabinoxylan from Rice
Bran (MGN-3). INT.Immunotherapy 14(2): 89-99.
5. Yeo W, Johnson P J (2006). Diagnosis, prevention and management of hepatitis B virus reactivation during
anticancer therapy. Hepatology 43(2): 209-220.
Hepatitis C
NAME/H.Y.
AGE/45
SEX/Male
AREA/Japan
History of Past Diseases and Treatments
In 1999, the patient was found to have AST and ALT levels of more than 100 in an annual health exam. He had a
complete medical checkup and was diagnosed with hepatitis C. He experienced significant fatigue and low energy.
He was recommended interferon therapy, but refused for fear of adverse effects. Regular injections with Stronger
Neo-Minophagen (an injectable glycyrrhiza) was the only alternative treatment he received. After six months, the level
of liver function enzymes increased gradually. AST increased to a maximum of 215 and ALT to a maximum of 408,
so he decided to try interferon therapy. Before starting interferon, he was given Rice Bran Arabinoxylan Compound
(RBAC) at 3g per day and was put on a vegetable-focused diet for one month as an attempt to enhance
immunopotency. After one month of RBAC treatment, AST and ALT were 20 and 28, respectively, therefore
interferon therapy was cancelled. He continues taking RBAC at 3g daily and the AST and ALT levels have been
maintained within normal limits.
Evaluation
Initial treatment was ineffective partly because he was in the habit of smoking and drinking. Since he gave up
19
smoking and drinking and switched to a diet centering on vegetables, RBAC showed a significant and swift effect.
The immunopotentiating effect (activation of NK cells and production of interferon) and liver-protecting effect of
RBAC resulted in a decrease of the viral count and eliminated liver inflammation.
NAME/T.K.
AGE/66
SEX/Female
AREA/Japan
History of Past Diseases and Treatments
In 1990, the patient was diagnosed with hepatitis C, but had no specific symptoms. In July 1995, a health checkup
revealed an abnormality in the liver. She had a complete medical checkup at the general hospital, which revealed a 3
cm liver cancer lesion. The treatment regimen involved infusing ethanol into the affected area. The patient was given
Rice Bran Arabinoxylan Compound (RBAC) at 3 g daily to reduce the adverse effect of the ethanol therapy and
protect the liver. Ethanol therapy was repeated seven times, and adverse effects such as fever, nausea and anorexia
were mild. The AFP value also decreased from 602.5 to 7.2, so the patient was discharged on the last day of
September. Although the AST and ALT values at discharge were 60 and 85, respectively, the examination performed
in February 1996 showed that the area treated with ethanol was necrotized, the tumor disappeared completely and
liver function normalized.
Changes caused by ingestion of RBAC
Within three days of treatment with RBAC, the patient began to improve and regained her appetite. She felt she could
endure the ethanol therapy with her increased physical strength and wished to recover her health completely.
Evaluation
Ethanol therapy is performed to solidify tumors with ethanol to prevent further growth, but it may cause inflammation
and pain in surrounding tissues. The immunopotentiating and liver-protective effect of RBAC reduced the adverse
effects of ethanol therapy and increased its effectiveness.
NAME/T.M.
AGE/60
SEX/Male
AREA/Japan
History of Past Diseases and Treatments
The patient began to feel malaise and fatigue in his lower limbs in April 1996. These symptoms persisted, so he
visited a hospital in September to undergo a complete medical checkup. Both the AST and ALT levels were about
400 and he was diagnosed with viral hepatitis C. He continued rest and dietary therapy and began receiving
treatment with interferon in June 1997. At this point in time, the AST and ALT levels were both between 180 and 190.
In addition to interferon, the patient took Rice Bran Arabinoxylan Compound (RBAC) at 3 g daily. He remained in the
hospital for the first two weeks of interferon treatment. During this period, no adverse effects were observed except a
fever of 39℃ or more. He was treated with interferon therapy for six months until late December, visiting the hospital
three times weekly. No adverse effects or attacks of fever occurred during this course, except for occasional bouts of
malaise associated with interferon injection. The AST and ALT values were within normal limits. Examinations in
January and May, 1998, revealed no viral reaction and showed complete remission. He is now taking RBAC at 2 g
daily to prevent recurrence.
Changes caused by ingestion of RBAC
Interferon is thought to cause strong adverse effects such as chills, anorexia and fever, however the patient did not
have serious adverse effects.
20
Case Reports
NAME/T.T.
Diabetes
AGE/55
SEX/Male
AREA/Japan
Clinical Record and Treatment
The patient was diagnosed with insulin-dependent diabetes mellitus in 1994. His blood sugar level was maintained
between 157~160 mg/dl by taking 12 units of insulin per day. After the patient began taking 3g of Rice Bran
Arabinoxylan Compound (RBAC) per day, he was able to reduce the insulin dosage to 6 units.
Changes caused by ingestion of RBAC
On the fifth day of RBAC treatment, the patient became hypoglycemic so insulin administration was reduced to 10
units. On the sixth day, the patient became hypoglycemic again and the insulin dosage was reduced to 8 units. The
th
third hypoglycemic event occurred on the 25 day, and the insulin dosage was then reduced to 6 units. Since then,
there have been reoccurrences of hypoglycemia. The patient now feels cured of diabetes and has declared that he
feels his life is worth living again.
NAME/K.N.
AGE/66
SEX/Male
AREA/Japan
History of Past Diseases and Treatments
In June 1993, the patient was finding that he had to get up several times during the night to urinate and had to drink
water frequently to satisfy his constant thirst. He went to the hospital for an examination and was diagnosed with
diabetes. His blood sugar level was 320 mg/dl. In September of that year, he was hospitalized and began to receive
treatment. His blood sugar level did not decrease until March 1994, when he was discharged, because he developed
hepatopathy, a possible complication from diabetes which delayed recovery. He continued treatment with insulin
injections at hospital visits but the fatigue did not disappear. He also had occasional attacks of asthma and was
feeling worse. At this point, he began taking Rice Bran Arabinoxylan Compound (RBAC) at a dose of 3 g daily. In
May, two months after starting to take RBAC, the blood sugar levels decreased to 110 mg/dl and insulin was no
longer necessary. Symptoms of asthma also began to improve and he had no asthma attacks from the autumn of
1994 to the spring of 1995. He is now feeling better and working every day. He still takes RBAC 1 g daily to maintain
health.
Changes caused by ingestion of RBAC
Seven days after starting to take RBAC, his malaise subsided and the patient had a comfortable awakening.
Symptoms of asthma also ameliorated and the sense of tightness in his throat disappeared.
NAME/Y.E.
AGE/58
SEX/Male
AREA/Japan
History of Past Diseases and Treatments
In the middle of November, 1996, the patient went to a nearby hospital and presented with abnormal fatigue. His
blood sugar level was 300 mg/dl and his glycohemoglobin (HbA1c) level was 9.8 and so was diagnosed with
diabetes. He also had complications from the disease; he was aware that he had been eating too many sweets since
the summer, but he attributed it to his fatigue. For the next month, he was put on a restricted diet and therapeutic
exercise that consisted of one hour of fast walking, but these therapies were not beneficial. Because he was told that
he had no choice but to undergo treatment with insulin, he went to K Hospital for additional treatments. K Hospital
recommended taking Rice Bran Arabinoxylan Compound (RBAC) at 3 g daily in addition to conventional treatment
21
with a restricted diet and exercise. One month after starting treatment with MGN-3, the blood sugar level decreased
to 98 mg/dl and the glycohemoglobin level to 7.2. He is now taking 1g RBAC daily.
Changes caused by ingestion of RBAC
He began to feel relief from his fatigue seven days after starting RBAC therapy. He no longer craved sweets and the
numbness in his limbs decreased day-by-day.
Case Reports
Herpes
NAME/R.S.
AGE/26
SEX/Female
AREA/Germany
16/02/2007-02/03/2007: Hospitalized
16/02/2007: Radiology: cranial MRI. Clinical indications: Lethargic patient, significant migraine with aura.
Assessment of the headache: visualization of left sided meningoencephalitis, temporomesial emphasis, e.g.
transmigration to left maxillary sinus. Recent cortical ischemia in temporal cortex. Because of localization, herpes
encephalitis must be ruled out stat. An immediate referral to the emergency room was advised. No signs of distress.
(the definition is “prison”).
22/02/2007: Confirmed diagnosis of herpes meningoencephalitis, left temporal. (A86) Anamnesis (preliminary case
history of a medical or psychiatric patient): The patient went to the emergency room on 12.02.07 because of a
massive headache spanning the neck to the top of the head, lasting three days. On 12.02.07 she noticed a
short-term right sided scotoma (partial visual interference), intermittent blurred vision with no other coexisting
vegetative symptoms (such as insomnia). An antiviral therapy with Zovirax by infusion was initiated.
02/03/2007: Initiate treatment of 3g of Rice Bran Arabinoxylan Compound (RBAC) daily for eight weeks.
23/04/2007: Evaluation of condition after herpes meningoencephalitis: approximately 3 cm sized area of damage in
the left temporal region with continued low grade cortical blood-brain barrier disorder. No other diffusion disorders.
Continued accompanying moderate grade, localized soft tissue edema. No signs of significant compression of
collateral brain structures. Furthermore,in the supra- as well as infratentorial there was an absence of brain
parenchyma signal changes. Medical evaluation: small damaged area in left-temporal region with only moderate
grade accompanying edema. No significant compression of collateral brain structure. No ischemia. No intracranial
bleeding
20/06/2007: Diagnosis: S/P herpes meningoencephalitis on left side, temporal (A86). Confirmed latent sensorimotor
hemiplegic symptoms left side (G81.9) Clinical evaluation: S/P herpes meningoencephalitis remains detectable on
neurological test with latent sensorimotor hemiplegic symptoms on left side. Activities of daily living were not
impacted. No further therapy is necessary.
February 2008: With exception of minor problems with short-term memory, the patient is free of complaints.
22